This filing is part of the company’s quarterly result. Read the full results article, with every figure explained →
Board meeting on Oct 22, 2026 to consider Q2/H1 FY26 results
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Board of Directors of Roselabs Finance will meet on Oct 22, 2026 to consider and approve unaudited financial results with limited review report for the quarter and half year ended Sept 30, 2026. The trading window for designated persons is shut from Oct 1, 2026 until 48 hours post declaration. No financial figures are disclosed in this advance intimation under SEBI Listing Regulation 29.
Routine procedural filing. Investors should await Q2 and H1 FY26 results on Oct 22 for any material business updates.
| Q2 FY27 | Q2 FY26 | Change | |
|---|---|---|---|
| Revenue | ₹0.00 Cr | ₹0.00 Cr | unchanged |
| Operating profit | −₹0.06 Cr | −₹0.06 Cr | loss widened |
| Profit after tax | −₹0.06 Cr | −₹0.06 Cr | loss widened |
| EBITDA margin | — | — | — |
From the company's XBRL filing, not from the text above. Operating profit = profit before tax − exceptional items − other income. EBITDA = profit before tax + finance costs + depreciation − other income.